1. Scrip
  2. >>Focus On Asia

Indian Court Rejects Bayer’s Plea to Halt Natco Sorafenib Exports

 
• By Vikas Dandekar

Bayer has suffered yet another setback in its long battle to defend its Nexavar patent in India. A recent decision permitted the local firm Natco to export a small quantity of sorafenib to Hisun of China.

MUMBAI – In a verdict that could lead to wider ramifications on exemptions allowed for drugs under a compulsory license, the Delhi High Court recently dismissed Bayer AG’s writ petition to block the export of a small quantity of sorafenib, the active ingredient of its kidney and liver cancer drug Nexavar, by Natco Pharma Ltd. to Chinese drug maker Hisun-Pfizer Pharmaceuticals Co. Ltd.

Natco had sought permission to export one kilogram of the API solely for the purpose of conducting development and clinical studies, as opposed to commercial sale

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.